Literature DB >> 12652391

Cryptosporidium species: new insights and old challenges.

Brett A Leav1, Melanie Mackay, Honorine D Ward.   

Abstract

Cryptosporidium species are protozoan parasites that cause mainly enteric illnesses in humans and other animals. The mode of transmission is most commonly waterborne, but other sources of infection, including foodborne and person-to-person spread, have been documented. The environmental form of the parasite is resistant to most water purification methods, including chlorination. Cryptosporidium infection usually causes a self-limited diarrheal illness but can be life-threatening in immunocompromised individuals. There is no effective therapy for cryptosporidiosis.

Entities:  

Mesh:

Year:  2003        PMID: 12652391     DOI: 10.1086/368194

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

Review 1.  Cryptosporidiosis: environmental, therapeutic, and preventive challenges.

Authors:  S Collinet-Adler; H D Ward
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

2.  Systemic antibody responses to the immunodominant p23 antigen and p23 polymorphisms in children with cryptosporidiosis in Bangladesh.

Authors:  Anoli J Borad; Geneve M Allison; David Wang; Sabeena Ahmed; Mohammad M Karim; Anne V Kane; Joy Moy; Patricia L Hibberd; Sitara Swarna Rao Ajjampur; Gagandeep Kang; Stephen B Calderwood; Edward T Ryan; Elena Naumova; Wasif A Khan; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

3.  Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Authors:  Jacob G Ludington; Honorine D Ward
Journal:  Curr Trop Med Rep       Date:  2015-09-01

4.  The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism.

Authors:  Steven P O'Hara; Aaron J Small; Jeremy B Nelson; Andrew D Badley; Xian-Ming Chen; Gregory J Gores; Nicholas F Larusso
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

5.  Quantification of in vitro and in vivo Cryptosporidium parvum infection by using real-time PCR.

Authors:  Nihal T Godiwala; Alain Vandewalle; Honorine D Ward; Brett A Leav
Journal:  Appl Environ Microbiol       Date:  2006-06       Impact factor: 4.792

6.  MyD88-dependent pathways mediate resistance to Cryptosporidium parvum infection in mice.

Authors:  K A Rogers; A B Rogers; B A Leav; A Sanchez; E Vannier; S Uematsu; S Akira; D Golenbock; H D Ward
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

7.  The Existing Drug Vorinostat as a New Lead Against Cryptosporidiosis by Targeting the Parasite Histone Deacetylases.

Authors:  Fengguang Guo; Haili Zhang; Nina N McNair; Jan R Mead; Guan Zhu
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

8.  Antibody responses to the immunodominant Cryptosporidium gp15 antigen and gp15 polymorphisms in a case-control study of cryptosporidiosis in children in Bangladesh.

Authors:  Genève M Allison; Kathleen A Rogers; Anoli Borad; Sabeena Ahmed; Mohammad Mahbubul Karim; Anne V Kane; Patricia L Hibberd; Elena N Naumova; Stephen B Calderwood; Edward T Ryan; Wasif A Khan; Honorine D Ward
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

9.  Proteolytic processing of the Cryptosporidium glycoprotein gp40/15 by human furin and by a parasite-derived furin-like protease activity.

Authors:  Jane W Wanyiri; Roberta O'Connor; Geneve Allison; Kami Kim; Anne Kane; Jiazhou Qiu; Andrew G Plaut; Honorine D Ward
Journal:  Infect Immun       Date:  2006-10-16       Impact factor: 3.441

10.  Role of murine Peyer's patch lymphocytes against primary and challenge infections with Cryptosporidium parvum.

Authors:  Sang-Mee Guk; Jong-Yil Chai
Journal:  Korean J Parasitol       Date:  2007-09       Impact factor: 1.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.